Tigris Ventures
Tigris Ventures is a seed-stage investment firm and venture incubator based in Houston, Texas, with a focus on identifying early-stage opportunities in the healthcare and environmental sectors, primarily in Southern California. Established in 2012, the firm manages over $20 million in capital, investing its own resources in ventures that demonstrate potential for significant impact and relatively modest exit valuations, typically between $2 million and $20 million. Tigris Ventures not only provides financial backing but also incubates certain start-ups, offering access to shared resources such as a development laboratory, CAD capabilities, and legal support. The firm evaluates investments based on criteria including innovation impact, intellectual property strength, market potential, and management experience, while engaging potential exit partners during the evaluation process to mitigate risk and enhance the likelihood of successful outcomes.
3 past transactions
Omniome
Series C in 2020
Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.
Alastin Skincare
Venture Round in 2019
Alastin Skincare is a California-based company that specializes in developing innovative and clinically-validated skincare products aimed at enhancing and maintaining healthy skin. Founded in 2015 and located in Carlsbad, the company focuses on creating physician-dispensed products that utilize advanced technology and a proprietary blend of peptides to support the skin's natural regeneration processes. Their offerings include solutions for both ablative and non-ablative rejuvenating procedures, ensuring that dermatologists and plastic surgeons can effectively assist their patients in correcting, protecting, and preserving their skin health. Alastin Skincare emphasizes safety and effectiveness through rigorous clinical testing of its products.
Tear Film Innovations
Series A in 2017
Tear Film Innovations Inc. is a San Diego-based company founded in 2014 that specializes in developing medical devices for the treatment of evaporative dry eye and related conditions, such as meibomian gland dysfunction and blepharitis. The company’s flagship product, the iLux Dry Eye Treatment System, is an FDA-cleared handheld device that allows eye care professionals to quickly evaluate and treat patients suffering from dry eye within ten minutes. This innovative system focuses on addressing blocked meibomian glands through targeted heating and compression, enhancing the efficiency of meibomian gland dysfunction treatment. As a subsidiary of Alcon, Inc., Tear Film Innovations aims to improve patient outcomes for the millions affected by evaporative dry eye worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.